LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD, Cardiovascular Cell Therapy Research Network
Tex Heart Inst J. 2010 37 (4): 412-20

PMID: 20844613 · PMCID: PMC2929864

MeSH Terms (18)

Angioplasty, Balloon, Coronary Bone Marrow Transplantation Double-Blind Method Echocardiography Heart Failure Humans Magnetic Resonance Imaging Myocardial Infarction Myocardium Pilot Projects Placebo Effect Research Design Time Factors Transplantation, Autologous Treatment Outcome United States Ventricular Function, Left Ventricular Remodeling

Connections (1)

This publication is referenced by other Labnodes entities: